The mts1 gene, encoding small Ca2+-binding protein of the S100-family,
is considered as a gene whose activity correlates with the manifestat
ion of a metastatic phenotype of tumor cells. It was shown before that
the mts1 is expressed not only in metastatic tumor cells but also in
some normal tissues, namely in so-called ''lymphoid'' organs: spleen,
thymus, bone marrow. In this work we analyzed in more detail the expre
ssion of mts1 in human and mouse hematopoietic cells and cell lines. A
high level of mts1 RNA was observed in T-lymphocytes, neutrophils, mo
nocytes/macrophages and in corresponding cell lines. Controversially,
the mts1 gene was silent in B-lymphocytes as well as in myeloma and er
ythroleukemia cell lines. The possibility of modulating the mts1 gene
expression by the action of different agents was demonstrated. Mitogen
s, such as lipopolysaccharides (LPS), interferon (IFN gamma), and conc
anavalin A (Con A), modulate the level of the mts1 gene expression in
hematopoietic cells differently. Calcium ionophore, A23187, can also b
e regarded as a modulator of the mts1 gene expression, since its addit
ion to the cells results in a substantial decrease of the mts1 RNA lev
el. It was shown that the mts1 RNA's half-life is relatively long, mor
e than 24 h. We therefore believe that calcium ionophore can activate
some ribonucleases which degrade the mts1 RNA. Cycloheximide prevents
the effect of A23187 and stabilizes the mts1 RNA, probably by blocking
the synthesis of these nucleases. Thus, the obtained data indicate th
at the agents which are capable of changing the physiological status o
f the cells also modulate the mts1 gene expression.